Danaher Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Julie Sawyer Montgomery
- Full Time Employees
- 60,000
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 2200 Pennsylvania Avenue, NW Washington DC United States 20037-1701
- IPO Date
- Dec 10, 1969
- CIK
- 0000313616
- Website
- danaher.com
- Similar Companies
- Business
- Danaher Corporation (NYSE: DHR), founded in 1984 and headquartered in Washington, D.C., operates as a leading global science and technology innovator focused on life sciences and diagnostics. The company conducts business through three primary segments: biotechnology, which develops products and services for therapeutic development including bioprocessing solutions, plasmid DNA, mRNA, proteins, and genomic medicines via brands such as Cytiva, Aldevron, and Abcam; life sciences, offering instruments like mass spectrometers, flow cytometry systems, microscopes, genomics consumables, lab automation, centrifugation, particle characterization, and gene and cell therapy tools; and diagnostics, providing clinical instruments, reagents, consumables, software, and services for disease diagnosis in hospitals, physicians' offices, reference laboratories, and critical care settings through subsidiaries including Cepheid and Beckman Coulter. Danaher serves customers worldwide across biopharmaceutical, research, healthcare, and precision medicine markets, employing approximately 63,000 associates in over 125 countries. Recent developments include the 2023 acquisition of Abcam for proteomic research consumables to accelerate drug discovery; a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics and precision medicine; and a May 2025 diagnostic development and commercialization alliance with AstraZeneca to scale next-generation AI-powered diagnostics solutions.
Company News
Danaher Q3 Recap: Decent Results, Still A Hold
Why Danaher Stock Bounced Higher Today
Danaher Corporation (DHR) Q3 2026 Earnings Call Transcript
Danaher: 3 Key Takeaways for Long-Term Investors
Danaher Corp (DHR) (Q3 2026) Earnings Call Highlights: Core Growth Accelerates to 5.5% Ex-Respiratory as EPS Guidance Rises
Danaher Q3 Review: Interested To See What The New Management Will Bring
DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
Danaher Q3 Earnings Call Highlights
Danaher (DHR) Reports Q3 Earnings: What Key Metrics Have to Say
Danaher (DHR) Tops Q3 Earnings and Revenue Estimates
Danaher Reports Third Quarter 2026 Results
Danaher Corporation $DHR Stock Holdings Lowered by Louisbourg Investments Inc.
Danaher Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Danaher Corporation $DHR Stock Bought by SteelPeak Wealth LLC
Danaher Corporation $DHR Stock: IFP Advisors Inc Increases Stake
Danaher Corporation $DHR Shares Bought by Birch Hill Investment Advisors LLC
2,506 Danaher Corporation $DHR Shares Acquired by Forbes J M & Co. LLP
15,838 Shares of Danaher Corporation $DHR Acquired by CWS Financial Advisors LLC
76,426 Shares in Danaher Corporation $DHR Bought by Aull & Monroe Investment Management Corp